PDGF receptor blocker for pulmonary hypertension: a new agent in therapeutic arsenal

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.21, Iss.2, 2012-02, pp. : 139-142

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting PDGF pathway in pulmonary arterial hypertension

By Antoniu Sabina Antonela

Expert Opinion on Therapeutic Targets, Vol. 16, Iss. 11, 2012-11 ,pp. : 1055-1063

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic potential of endothelin receptor antagonists and nitric oxide donors in pulmonary hypertension

By Tilton Ronald G Brock Tommy A Dixon Richard AF

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 7, 2001-07 ,pp. : 1291-1308

Informa Healthcare

Access to resources Recommend Favorite

Endothelin receptor antagonism: a new approach in the treatment of pulmonary hypertension

Inpharma, Vol. 1, Iss. 1311, 2001-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Therapeutic Peptides: New Arsenal Against Drug Resistant Pathogens

Current Pharmaceutical Design, Vol. 20, Iss. 5, 2014-02 ,pp. : 771-792

Bentham Science Publishers

Access to resources Recommend Favorite

Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?

By Barrios Vivencio Escobar Carlos

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 16, 2013-11 ,pp. : 2249-2261

Informa Healthcare

Access to resources Recommend Favorite